Your browser doesn't support javascript.
loading
CHD1 loss sensitizes prostate cancer to DNA damaging therapy by promoting error-prone double-strand break repair.
Shenoy, T R; Boysen, G; Wang, M Y; Xu, Q Z; Guo, W; Koh, F M; Wang, C; Zhang, L Z; Wang, Y; Gil, V; Aziz, S; Christova, R; Rodrigues, D N; Crespo, M; Rescigno, P; Tunariu, N; Riisnaes, R; Zafeiriou, Z; Flohr, P; Yuan, W; Knight, E; Swain, A; Ramalho-Santos, M; Xu, D Y; de Bono, J; Wu, H.
Affiliation
  • Shenoy TR; Department of Molecular and Medical Pharmacology, University of California, Los Angeles, USA.
  • Boysen G; The Institute of Cancer Research, London, UK.
  • Wang MY; Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust, London, UK.
  • Xu QZ; The MOE Key Laboratory of Cell Proliferation and Differentiation, School of Life Sciences, Peking-Tsinghua Center for Life Sciences, Peking University, Beijing, China.
  • Guo W; The MOE Key Laboratory of Cell Proliferation and Differentiation, School of Life Sciences, Peking-Tsinghua Center for Life Sciences, Peking University, Beijing, China.
  • Koh FM; The MOE Key Laboratory of Cell Proliferation and Differentiation, School of Life Sciences, Peking-Tsinghua Center for Life Sciences, Peking University, Beijing, China.
  • Wang C; Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research and Center for Reproductive Sciences, Department of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco, USA.
  • Zhang LZ; Department of Molecular and Medical Pharmacology, University of California, Los Angeles, USA.
  • Wang Y; The MOE Key Laboratory of Cell Proliferation and Differentiation, School of Life Sciences, Peking-Tsinghua Center for Life Sciences, Peking University, Beijing, China.
  • Gil V; Department of Molecular and Medical Pharmacology, University of California, Los Angeles, USA.
  • Aziz S; The Institute of Cancer Research, London, UK.
  • Christova R; The Institute of Cancer Research, London, UK.
  • Rodrigues DN; The Institute of Cancer Research, London, UK.
  • Crespo M; The Institute of Cancer Research, London, UK.
  • Rescigno P; Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust, London, UK.
  • Tunariu N; The Institute of Cancer Research, London, UK.
  • Riisnaes R; Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust, London, UK.
  • Zafeiriou Z; Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust, London, UK.
  • Flohr P; Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust, London, UK.
  • Yuan W; The Institute of Cancer Research, London, UK.
  • Knight E; Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust, London, UK.
  • Swain A; Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust, London, UK.
  • Ramalho-Santos M; The Institute of Cancer Research, London, UK.
  • Xu DY; Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust, London, UK.
  • de Bono J; The Institute of Cancer Research, London, UK.
  • Wu H; The Institute of Cancer Research, London, UK.
Ann Oncol ; 28(7): 1495-1507, 2017 Jul 01.
Article in En | MEDLINE | ID: mdl-28383660
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / Cross-Linking Reagents / DNA Breaks, Double-Stranded / Cdh1 Proteins / Poly(ADP-ribose) Polymerase Inhibitors Type of study: Prognostic_studies Limits: Animals / Humans / Male Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2017 Document type: Article Affiliation country: United States Country of publication: United kingdom
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / Cross-Linking Reagents / DNA Breaks, Double-Stranded / Cdh1 Proteins / Poly(ADP-ribose) Polymerase Inhibitors Type of study: Prognostic_studies Limits: Animals / Humans / Male Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2017 Document type: Article Affiliation country: United States Country of publication: United kingdom